Mois : février 2020

Marijuana Use Continues to Grow in Older Adults, Pauline Anderson, Medscape, 26 February 2020

Marijuana Use Continues to Grow in Older Adults Pauline Anderson Medscape, February 26, 2020 https://www.medscape.com/viewarticle/925762?nlid=134178_2052&src=WNL_mdplsnews_200228_mscpedit_psyc&uac=292598PZ&spon=12&impID=2294726&faf=1   Cannabis use in older Americans is growing. New research shows that over a 4-year period use of the drug in individuals age 65 and older increased by 75%. Joseph J. Palamar, PhD, MPH This population is especially vulnerable to potential adverse effects from cannabis and so this population needs to understand the potential risks associated with marijuana use, study investigator Joseph J. Palamar, PhD, MPH, associate professor, Department of Population Health, New York University (NYU) Langone Medical Center, New York City, told Medscape Medical News. The findings, he added, indicate a need for more [...]

Lire la suite

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs, Hector Lafuente et al., 2011

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs Hector LAFUENTE, Francisco J. ALVAREZ, M. Ruth PAZOS, Antonia ALVAREZ, M. Carmen REY-SANTANO, Victoria MIELGO, Xabier MURGIA-ESTEVE, Enrique HILARIO, and Jose MARTINEZ-ORGADO Pediatric Research, 2011, 70, 272–277. ABSTRACT : Newborn piglets exposed to acute hypoxia-ischemia (HI) received i.v. cannabidiol (HI CBD) or vehicle (HI VEH). In HI VEH, 72 h post-HI brain activity as assessed by amplitudeintegrated EEG (aEEG) had only recovered to 42 9% of baseline, near-infrared spectroscopy (NIRS) parameters remained lower than normal, and neurobehavioral performance was abnormal (27.8 2.3 points, normal 36). [...]

Lire la suite

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts, Natasha L. Mason et al., 2020,

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts Natasha L. Mason, Patrick C. Dolder and Kim P.C. Kuypers Drug Science, Policy and Law, 2020, Volume 6, 1–11. Doi : 10.1177/2050324519900068   Abstract Background : It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome [...]

Lire la suite

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study, Khalid A. Jadoon et al., 2017

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study Khalid A. Jadoon, Garry D. Tan, and Saoirse E. O’Sullivan JCI Insight, 2017, 2, (11), e93760 Doi : 10.1172/jci.insight.93760   BACKGROUND. Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans. METHODS. Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using [...]

Lire la suite

Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen-glucose deprivation via PPARγ and 5- HT1A receptors, William H Hind et al., 2016.

Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors William H Hind, Timothy J England and Saoirse E O’Sullivan British Journal of Pharmacology, 2016, 173, 815–825. Doi : 10.1111/bph.13368   BACKGROUND AND PURPOSE In vivo and in vitro studies have demonstrated a protective effect of cannabidiol (CBD) in reducing infarct size in stroke models and against epithelial barrier damage in numerous disease models. We aimed to investigate whether CBD also affects blood–brain barrier (BBB) permeability following ischaemia. EXPERIMENTAL APPROACH Human brain microvascular endothelial cell (HBMEC) and human astrocyte co-cultures modelled the BBB. Ischaemia was modelled by oxygen–glucose deprivation (OGD) [...]

Lire la suite

Cannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System, Audrey Lefebvre, 2016

Cannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System Audrey Lefebvre wakeup-world.com/2016/03/20/cannabis-as-medicine-how-cbd-cannabidiol-benefits-the-human-brainand-nervous-system/   Cannabidiol (CBD) is an active cannabinoid found in cannabis which, unlike THC (tetrahydro-cannabinol), does not produce a psychoactive effect in the brain. For this reason, CBD has become a primary focus of medicinal cannabis studies. CBD has been found to have a wide range of benefits, including lowering blood sugar levels, promoting bone growth, and importantly, protecting the human brain and nervous system from degeneration. How CBD Protects the Nervous System The nervous system is comprised of two main parts: the peripheral nervous system, which includes the nerves and ganglia on [...]

Lire la suite

Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized- Controlled Clinical Trials, Juan Jose Fuentes et al., 2020

Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials Juan José Fuentes, Francina Fonseca, Matilde Elices, Magí Farré and Marta Torrens Frontiers in Psychiatry, 2020, Vol 10, Article 943. doi : 10.3389/fpsyt.2019.00943   Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and [...]

Lire la suite

Therapeutic Potential of Psychedelic Drugs, Justin Briglio, 2015

Therapeutic Potential of Psychedelic Drugs Justin Briglio University of Maine, 2015, 31 p.   Table of Contents Introduction......................................................................................................................................3 History of Psychedelic Research.....................................................................................................6 Recent Research...............................................................................................................................8 Neurobiology of Psychedelics.........................................................................................................9 Therapeutic Potential of Psilocybin...............................................................................................12 Therapeutic Potential of LSD........................................................................................................15 Therapeutic Potential of Ayahuasca..............................................................................................19 Therapeutic Potential of Ibogaine..................................................................................................22 Conclusion.....................................................................................................................................26 References......................................................................................................................................28 A psychedelic compound is a psychoactive drug whose main action is to alter perception and cognition. Psychedelics are distinctive from other psychoactive drugs in that they alter the mind, whereas opiates or stimulants alter the mood (Meyer & Quenzer, 2013). Psychedelics affect nature of consciousness itself and access otherwise unknown states of consciousness, as opposed to affecting the degree or extent of one's consciousness and inducing proverbial moods such as [...]

Lire la suite

Is there a role for cannabidiol in psychiatry ?, Julia Machado Khoury et al., 2017

Is there a role for cannabidiol in psychiatry ? Julia Machado Khoury , Maila de Castro Lourenço das Neves, Marco Antônio Valente Roque, Daniela Alves de Brito Queiroz , Andre Augusto Corrêa de Freitas, Angelo de Fatima, Fabrıcio Moreira and Frederico Duarte Garcia The World Journal of Biological Psychiatry, 2017, 16 p. Doi : 10.1080/15622975.2017.1285049   ABSTRACT Objectives : Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic [...]

Lire la suite

LSD : microdoses festives, Céline Zünd, Le Temps, mardi 28 janvier 2020

LSD : microdoses festives Céline ZÜND Le Temps, mardi 28 janvier 2020 https://www.letemps.ch/societe/lsd-microdoses-festives?utm_campaign=article_traffic&utm_content=1580242382&utm_medium=social&utm_source=facebook&fbclid=IwAR3v1uDm_lCzk_Bb1XMeRzSxcxr-mHObGhhPeJVK-Fa0y6rczvc3DFJ3H78   La prise de LSD en petites quantités fait toujours plus d'adeptes, dans les milieux festifs, au travail ou en automédication. Or la recherche scientifique ne dispose pas de données fiables sur les véritables effets de cette substance, ni sur ses risques potentiels. Ursina s’est longtemps refusée à la tentation d’accompagner ses nuits festives de substances chimiques. «J’avais peur du mauvais trip», dit la Zurichoise de 40 ans, casquette et bomber satiné. Jusqu’à ce qu’elle entende parler du LSD en microdose. Elle se procure l’hallucinogène une première fois il y [...]

Lire la suite